How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

60 results for

Eflornithine Cream

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Eflornithine Cream

Eflornithine Cream Eflornithine Cream Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Eflornithine Cream Eflornithine Cream Aka (...) : Eflornithine Cream , Vaniqa From Related Chapters II. Indications : Removal of unwanted facial hair in women III. Pharmacology Irreversible inhibitor of ornithine decarboxylase Inhibits polyamine biosynthesis Decreases polyamine mediated cell division Prior systemic use for African Trypanosomiasis Peak systemic absorption <10 ng/ml IV. Adverse Effects: Local irritation Stinging or burning Tingling V. Dosing (30 gram tube costs pharmacist $42) Apply thin layer to affected area bid Doses should be at least 8

2018 FP Notebook

2. Eflornithine Cream

Eflornithine Cream Eflornithine Cream Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Eflornithine Cream Eflornithine Cream Aka (...) : Eflornithine Cream , Vaniqa From Related Chapters II. Indications : Removal of unwanted facial hair in women III. Pharmacology Irreversible inhibitor of ornithine decarboxylase Inhibits polyamine biosynthesis Decreases polyamine mediated cell division Prior systemic use for African Trypanosomiasis Peak systemic absorption <10 ng/ml IV. Adverse Effects: Local irritation Stinging or burning Tingling V. Dosing (30 gram tube costs pharmacist $42) Apply thin layer to affected area bid Doses should be at least 8

2015 FP Notebook

3. Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism

Information provided by (Responsible Party): Elisabeth Taudorf, Bispebjerg Hospital Study Details Study Description Go to Brief Summary: Split-face investigation of the efficacy of applying Eflornithin cream twice daily for six months after a period with six laser treatments for hair removal. Condition or disease Intervention/treatment Phase Hirsutism Drug: Eflornithine cream 11.5 w/w % Phase 4 Detailed Description: Background: Unwanted facial hair growth is a serious problem for 5-15% of all women winch (...) affects their quality of life. In Denmark patients are offered six laser treatments covered by the public health insurance. There is a lack of good follow-up treatments to this regime that can extent the efficacy of the laser treatment. Eflornithin cream is an approved treatment for reduction of facial hair growth which has proved to give an additional efficiency when used in combination with laser treatments.The efficacy when used after laser hair removal is not known. Aim: To investigate whether

2013 Clinical Trials

4. Topical eflornithine hydrochloride improves the effectiveness of standard laser hair removal for treating pseudofolliculitis barbae: a randomized, double-blinded, placebo-controlled trial. (PubMed)

laser treatments, patients applied eflornithine and placebo creams twice daily to opposite sides of the bearded neck region. The number of hairs and inflammatory papules were counted bilaterally at each visit.The eflornithine side had a statistically significant decrease in the number of hairs and inflammatory papules compared with the placebo side. At 16 weeks, the eflornithine side had a median hair reduction of 99.5% from baseline (range 48.5%-100.0%), whereas the placebo side had an 85.0% median (...) Topical eflornithine hydrochloride improves the effectiveness of standard laser hair removal for treating pseudofolliculitis barbae: a randomized, double-blinded, placebo-controlled trial. Pseudofolliculitis barbae (PFB) significantly impacts the military population, especially deployed personnel.This study was designed to determine whether the addition of topical eflornithine to hair laser treatment would improve efficacy in treating PFB.This was a randomized, double-blinded, placebo

2012 Journal of the American Academy of Dermatology

6. Screening and Management of the Hyperandrogenic Adolescent

and darker hair (24). In patients with darker skin types, hair reduction also is achievable with laser therapy using longer wavelengths and appropriate energy settings (25). Eflornithine cream is approved for the treatment of facial hirsutism and is a topical inhibitor of L-ornithine decarboxylase, the enzyme critical to cell growth and differentiationwithinthehairfollicle.Continuoustopical administration slows facial hair growth, but is limited to small areas of use, and hair growth recurs when (...) clinical eval- uation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Eflornithine HCl Study Group. Int J Dermatol 2007; 46:94–8. 27. Eichenfield LF, Krakowski AC, Piggott C, Del Rosso J, Baldwin H, Friedlander SF, et al. Evidence-based recom- mendations for the diagnosis and treatment of pediatric acne. American Acne and Rosacea Society. Pediatrics 2013;131(suppl 3):163–86. 28. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why

2019 American College of Obstetricians and Gynecologists

7. Evaluation and Treatment of Hirsutism in Premenopausal Women

of developing paradoxical hypertrichosis (PH) with photoepilation therapy. We suggest topical treatment or electrolysis over photoepilation with these patients. (2 |⊕⊕OO) 4.3. For women who desire more rapid response to photoepilation, we suggest adding eflornithine topical cream during treatment. (2 |⊕⊕OO) 4.4. For women with known hyperandrogenemia who choose hair removal therapy, we suggest pharmacologic therapy to minimize hair regrowth. (2 |⊕⊕OO) Changes Since the Previous Guideline In 2008

Full Text available with Trip Pro

2018 The Endocrine Society

8. Evaluation and Treatment of Hirsutism in Premenopausal Women

of developing paradoxical hypertrichosis (PH) with photoepilation therapy. We suggest topical treatment or electrolysis over photoepilation with these patients. (2 |⊕⊕OO) 4.3. For women who desire more rapid response to photoepilation, we suggest adding eflornithine topical cream during treatment. (2 |⊕⊕OO) 4.4. For women with known hyperandrogenemia who choose hair removal therapy, we suggest pharmacologic therapy to minimize hair regrowth. (2 |⊕⊕OO) Changes Since the Previous Guideline In 2008

Full Text available with Trip Pro

2018 The Endocrine Society

9. Menopause Chapter 2: Midlife Body Changes

or keratin fibers may be used as an alternative to achieve sufficient density for the frontal hair loss in FPHL. (Level II) Treatment for hirsutism focuses on a combination of hormonal therapies, peripheral androgen blockage, and mechanical depilation. Eflornithine hydrochloride is an FDA-approved topical cream that reduces the growth of unwanted facial hair in women. Waxing, bleaching, shaving, and laser treatment are other options for managing hirsutism. (Level II) EYES Key Points One of the most

2014 The North American Menopause Society

11. Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases (PubMed)

Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases The fluorinated ornithine analog α-difluoromethylornithine (DFMO, eflornithine, ornidyl) is an irreversible suicide inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme of polyamine biosynthesis. The ubiquitous and essential polyamines have many functions, but are primarily important for rapidly proliferating (...) in the hair removal cream Vaniqa. In recent years, renewed interest in DFMO for hyperproliferative diseases has led to increased research and promising preclinical and clinical trials. This review explores the use of DFMO for the treatment of African sleeping sickness and hirsutism, as well as its potential as a chemopreventive and chemotherapeutic agent against colorectal cancer and neuroblastoma.

Full Text available with Trip Pro

2018 Medical Sciences

12. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline

) Cyclic progestins (eg, 10 mg medroxyprogesterone acetate 10–14 days every 2–3 months) Metformin (improves ovulation and menstral cyclicity) Hirsutism Choice of options depends on patient preferences; impact on wellbeing; and access and affordability: Self-administered and professional cosmetic therapy are first line (laser recommended) Eflornithine cream can be added and may induce a more rapid response If cosmetic therapy is not adequate, pharmacological therapy can be considered Pharmacological

2011 MJA Clinical Guidelines

13. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline

) Cyclic progestins (eg, 10 mg medroxyprogesterone acetate 10–14 days every 2–3 months) Metformin (improves ovulation and menstral cyclicity) Hirsutism Choice of options depends on patient preferences; impact on wellbeing; and access and affordability: Self-administered and professional cosmetic therapy are first line (laser recommended) Eflornithine cream can be added and may induce a more rapid response If cosmetic therapy is not adequate, pharmacological therapy can be considered Pharmacological

2011 MJA Clinical Guidelines

14. Hair Removal Technique

Galvanic (DC): Multiple treatments required (slow) Thermolysis (Alternating Current) Adverse effects Pain with procedure Risk of , scarring or pigmentation changes VII. Technique: Topical agents: Eflornithine Cream (Vaniqa) Apply bid to involved face Not first-line (often used to augment other methods) Works well in combination with laser Effective within 4-8 weeks of regular use normalizes 8 weeks after discontinuation Risk of and local irritation VIII. References Hansen (1997) Female Patient 22:11-18

2018 FP Notebook

15. Hirsutism

secretion Alter ( ) binding Impair peripheral androgen precursor conversion Inhibit androgen action at target tissue ral Measures Weight loss if present (lowers androgens) See s Medications: First line s Lowers : Decreases Testosterone production Increase Serum : Increases Testosterone binding Decreases (unbound) levels Lowest ( , ) ( , ) ( ) Ethynodiol ( ) 100 to 200 mg PO divided bid to tid Category D medication in pregnancy Eflornithine ( ) 13.9% cream FDA approved only for unwanted facial hair May

2018 FP Notebook

16. Hirsutism

cream (for facial hirsutism in women aged 19 years and older). A combined oral contraceptive (COC), provided there are no contraindications (such as uncontrolled hypertension and current breast cancer). Options are Dianette ® (co-cyprindiol, licensed use) or a COC containing drospirenone (for example Yasmin ® , unlicensed use). Management options in primary care for postmenopausal women include: Cosmetic hair reduction and removal. Eflornithine cream (for facial hirsutism). Weight loss (if obese (...) [ ]. A prescribing information section for eflornithine cream has also been added. Previous changes Previous changes May 2013 — minor update. Eflornithine cream is now only licensed for women over 18 years of age. The text and the prescriptions have been amended to reflect this. June 2011 — minor update. Broken link fixed. Issued June 2011. September 2009 to January 2010 — this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked

2014 NICE Clinical Knowledge Summaries

17. Nonlaser Hair Removal Techniques (Overview)

methods are available for temporary or permanent hair removal, each with its own relative efficacy and adverse effects. Different methods for the removal of body hair include the following: Temporary hair removal: Shaving, epilation, depilation, bleaching [ ] Temporary hair reduction: Eflornithine hydrochloride (VANIQA cream 13.9%) Permanent hair reduction: Intense pulsed light, laser-assisted hair removal Permanent hair removal: Electrolysis The development of home-use devices is increasing (...) include skin irritation, temporary skin discoloration, pruritus, and the prominent appearance of bleached hair against tanned or naturally dark skin. Reports exist of generalized urticaria, asthma, syncope, and shock in reaction to the persulfate activator added to boost the effect of hydrogen peroxide bleach. Previous Next: Temporary Hair Reduction Eflornithine Eflornithine (VANIQA) is a topical cream available by prescription in the United States. It has been approved by the US Food and Drug

2014 eMedicine.com

18. Congenital Hypertrichosis Lanuginosa (Follow-up)

=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTA3Mjk4Ny10cmVhdG1lbnQ= processing > Congenital Hypertrichosis Lanuginosa Treatment & Management Updated: Aug 28, 2018 Author: Dirk M Elston, MD; Chief Editor: William D James, MD Share Email Print Feedback Close Sections Sections Congenital Hypertrichosis Lanuginosa Treatment Medical Care The use of eflornithine (Vaniqa cream) 13.9% or hair removal by means of repeated shaving, depilatory methods (eg, chemical, electric methods), or bleaching can improve congenital hypertrichosis lanuginosa (CHL) patients

2014 eMedicine.com

19. Pseudofolliculitis of the Beard (Treatment)

that the hair becomes embedded in upon emerging from the follicle. [ , ] Topical combination cream (tretinoin 0.05%, fluocinolone acetonide 0.01%, and hydroquinone 4%) (Triluma) has been shown to provide some benefit by targeting the hyperkeratosis (tretinoin), inflammation (fluocinolone), and postinflammatory hyperpigmentation (hydroquinone). [ ] Mild topical corticosteroid creams reduce inflammation of papular lesions. [ ] Topical eflornithine HCL 13.9% cream (Vaniqa) has been used for excessive facial (...) . . Childs ND. Tretinoin, hydrocortisone cream controls PFB. Skin and Allergy News . 1999. 30(5):20. Kligman AM, Mills OH Jr. Pseudofolliculitis of the beard and topically applied tretinoin. Arch Dermatol . 1973 Apr. 107(4):551-2. . Taylor S. Open-Label Case Study on Triple-Combination Cream in Patients with Pseudofolliculitis Barbae. J Am Acad Dermatol . 2005. 52:P169. Callender V, Young CM. Combination Laser and Eflornithine HCL 13.9% Cream: A First-line Therapy for Fitzpatrick Type IV-VI Patients

2014 eMedicine.com

20. Congenital Hypertrichosis Lanuginosa (Treatment)

=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTA3Mjk4Ny10cmVhdG1lbnQ= processing > Congenital Hypertrichosis Lanuginosa Treatment & Management Updated: Aug 28, 2018 Author: Dirk M Elston, MD; Chief Editor: William D James, MD Share Email Print Feedback Close Sections Sections Congenital Hypertrichosis Lanuginosa Treatment Medical Care The use of eflornithine (Vaniqa cream) 13.9% or hair removal by means of repeated shaving, depilatory methods (eg, chemical, electric methods), or bleaching can improve congenital hypertrichosis lanuginosa (CHL) patients

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>